Guggenheim initiated coverage of Claritev with a rating of Buy and set a new price target of $43.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2026 | $32.00 | Buy | Canaccord Genuity |
| 4/24/2026 | $28.00 | Overweight | Barclays |
| 1/12/2026 | $43.00 | Buy | Guggenheim |
| 1/9/2026 | $33.00 | Equal Weight | Wells Fargo |
| 10/21/2025 | $74.00 | Neutral → Buy | Citigroup |
| 5/29/2025 | $44.00 | Neutral → Overweight | Piper Sandler |
New Primary Network Solution Helps Balance Regional Access, National Reach, and Cost Discipline As healthcare costs accelerate and employers demand more control over network strategy, Claritev Corporation (NYSE:CTEV), a healthcare technology, data and insights company, today announced the launch of PHCS Novera, a primary network solution designed to help deliver flexible, competitive options. With nearly two-thirds of covered workers enrolled in self-funded insurance plans and healthcare costs projected to rise 9.5% in 2026, employers are increasingly pushing third-party administrators (TPAs) to deliver more flexible, cost-conscious network designs. PHCS Novera was built to meet that de
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors and host a presentation at the BofA Securities 2026 Global Health Care Conference in Las Vegas. The Company will webcast its presentation scheduled for 5:00 pm PT on Wednesday, May 13, 2026. To listen to the webcast, please visit https://investors.claritev.com/events-and-presentations/. For one-on-one meetings, please contact a representative at the host firm. About Claritev Claritev is a healthcare technology, data, and insights co
Q1 2026 Revenues of $244.7 million grew 5.8% compared to Q1 2025 Net Loss of $73.6 million Adjusted EBITDA of $146.9 million increased 3.4% compared to Q1 2025 (Adjusted EBITDA Margin of 60.0% versus 61.4% in Q1 2025) Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2026. "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence — confidence in our te
8-K - Claritev Corp (0001793229) (Filer)
Canaccord Genuity initiated coverage of Claritev with a rating of Buy and set a new price target of $32.00
Barclays initiated coverage of Claritev with a rating of Overweight and set a new price target of $28.00
Guggenheim initiated coverage of Claritev with a rating of Buy and set a new price target of $43.00
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
Third annual report highlights the company's commitment to social and environmental stewardship Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the publication of its 2024 Corporate Responsibility Report. The 2024 report showcases the Company's strategic momentum in advancing its sustainability priorities during a pivotal year of transformation. The report emphasizes Claritev's continued focus on managing, tracking and disclosing its social and environmental performance, reinforcing its commitment to accountability and responsible
Strategic leadership and operational collaboration underscore Claritev's commitment to growth in the Middle East and international business development outside the US Claritev Corporation ("Claritev") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it is deepening its investment in the Middle East North Africa ("MENA") region and the market outside the United States with the appointment of new regional leadership and a strategic operational collaboration. These moves reflect Claritev's continued focus on expanding its footprint and delivering localized, high-impact healthcare technology soluti
HOLLYWOOD, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Great Speech, a national leader in virtual speech therapy, is proud to announce a new agreement with Claritev, formerly known as MultiPlan (NYSE:CTEV), a technology and data insights company focused on making healthcare more affordable, transparent and fair for all. This network participation agreement marks a major step forward in expanding access to high-quality, convenient, and personalized speech therapy services for individuals and families nationwide. Great Speech's innovative teletherapy services will now be available to health plan members accessing Claritev's MultiPlan and PHCS Networks. The initiative aims to eliminate traditio
Q1 2026 Revenues of $244.7 million grew 5.8% compared to Q1 2025 Net Loss of $73.6 million Adjusted EBITDA of $146.9 million increased 3.4% compared to Q1 2025 (Adjusted EBITDA Margin of 60.0% versus 61.4% in Q1 2025) Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2026. "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence — confidence in our te
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its first quarter fiscal year 2026 financial results prior to market open on Thursday, May 7, 2026, and hold a conference call at 8:00 am Eastern Time. A live webcast of the conference call can be accessed through the Investor Relations section of the Company's website at investors.claritev.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. The earnings press release and supplemental slide deck
Q4 2025 Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%) Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024) Full-year 2026 Guidance initiated: Revenue range of $980 million to $1 billion Free cash flow of $0 million to $10 million Capital expenditures of $160 million to $170 million Company Board of Directors approves $75 million, five-year share repurchase program Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insigh